A Phase 1 Randomized Double-Blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis or Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2018
At a glance
- Drugs EDP-1815 (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions; First in man
- Sponsors Evelo Biosciences
- 26 Nov 2018 According to an Evelo Biosciences media release, the company expects to report initial clinical data from this trial in the second half of 2019.
- 26 Nov 2018 According to an Evelo Biosciences media release, the company today announced the first dosing in this phase Ib trial.
- 05 Nov 2018 Status changed from planning to recruiting.